Gossamer Bio stock heads toward October 27 vote after Nasdaq win

Gossamer Bio stock (ISIN US38341P2011) was last at USD 10.65 on Nasdaq on October 5, 2026, down 0.56 percent from the prior close. The company restored compliance with Nasdaq's minimum bid price rule after a 1-for-80 reverse stock split, while a stockholder vote on October 27, 2026, will address a proposed financing structure.

Nasdaq status is restored

According to StockTitan, Nasdaq notified Gossamer Bio on September 25, 2026, that the company had regained compliance with Listing Rule 5450(a)(1). The matter followed 30 consecutive business days below Nasdaq's USD 1.00 minimum bid price threshold.

The company implemented the 1-for-80 reverse split on September 10, 2026, and split-adjusted trading began on September 11, 2026, according to the same 8-K filing. The action addressed the listing requirement, but it also makes the post-split share price and future dilution terms central to the investment case.

Seralutinib remains the operating driver

Gossamer Bio said on September 23, 2026, that it submitted a New Drug Application to the U.S. Food and Drug Administration for seralutinib in pulmonary arterial hypertension. The company describes seralutinib as its main development program for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The latest reported quarter ended June 30, 2026. According to Investing.com, revenue was USD 9.238 million, compared with USD 16.955 million in the prior quarter, while net income swung from a USD 46.664 million loss to USD 16.900 million. The revenue comparison represents a 45.52 percent decline, whereas the earnings change reflects a return to positive net income.

Vote sets the next financing test

Gossamer Bio's virtual special meeting is scheduled for October 27, 2026, at 9:00 a.m. Pacific Time, according to the company's proxy filing published by StockTitan. The proposal covers issuance of common stock underlying pre-funded warrants, FDA approval warrants and convertible preferred stock.

The financing links additional capital to regulatory milestones for seralutinib. That structure gives the October vote direct importance for funding capacity and potential dilution, especially after the reverse split reduced the number of shares outstanding on a split-adjusted basis.

Consensus target remains elevated

MarketScreener lists an Outperform consensus from 7 analysts, with an average target of USD 122.48 and a published reference price of USD 11.28 on September 22, 2026. The average target stood 985.82 percent above that reference price, underscoring the unusually wide gap between the current valuation and analyst expectations.

GOSS stays near its yearly low

GOSS was last at USD 10.65 on Nasdaq on October 5, 2026, with a session range of USD 10.01 to USD 10.74 and volume of 390,012 shares. Its 52-week range was USD 9.10 to USD 309.60, while market capitalization stood at USD 65.1 million.

Upcoming dates for Gossamer Bio stock

• October 27, 2026: Virtual special meeting of stockholders

More news and analyses on Gossamer Bio stock